Home Jazz Is Jazz Pharmaceuticals PLC (JAZZ) a Good Buy in the Biotech Industry?

Is Jazz Pharmaceuticals PLC (JAZZ) a Good Buy in the Biotech Industry?


Hill 64 InvestorsObserver puts shares of Jazz Pharmaceuticals PLC (JAZZ) near the top of the biotechnology industry. In addition to scoring more than 96% of biotech stocks, JAZZ’s overall rating of 64 means the stock scores better than 64% of all stocks.

JAZZ has an overall score of 64. Find out what this means for you and get the rest of the rankings on JAZZ!

What do these notes mean?

Finding the best stocks to invest in can be difficult. There are thousands of options and it can be confusing to know what really constitutes great value. InvestorsObserver lets you choose from eight unique metrics to display the top industries and top performing stocks within that industry. A score of 64 would be higher than 64% of all actions. This ranking system incorporates many factors used by analysts to compare stocks in more detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis provide investors with an easy way to see the attractiveness of specific stocks. Stocks with the highest scores have the best valuations by analysts working on Wall Street.

What’s going on with Jazz Pharmaceuticals PLC shares today?

Jazz Pharmaceuticals PLC (JAZZ) stock is trading at $145.26 at 2:32 p.m. on Tuesday, February 15, up $2.96, or 2.08% from the previous closing price of 142.31 $. The stock has traded between $142.42 and $146.45 so far today. The volume today is light. So far, 248,478 shares have been traded against an average volume of 654,188 shares. Click here for the full Jazz Pharmaceuticals PLC stock report.

Stay in the know

Subscribe to our daily morning update newsletter and never miss market news, moves and more.

Thank you for signing up! You are ready to receive the Morning Update newsletter